Dendritic cells (DCs) are the most potent professional APCs and play an important role in cancer immune response. With the rapid development of DC-based cancer vaccines, tumor-DC hybrids are the most effective ones —— they could present antigens and keep on producing endogenous antigens. The tumor-DC hybrids are currently being evaluated in many animal and clinical trials, available published data showed that hybrids could induce tumor specific T lymphocyte response and be well-tolerated in patients. The progress of tumor-DC hybrids, as well as some issues was discussed.